Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 16;27(16):5236.
doi: 10.3390/molecules27165236.

Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment

Affiliations
Review

Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment

Salar Hafez Ghoran et al. Molecules. .

Abstract

Throughout the United States, cancer remains the second leading cause of death. Traditional treatments induce significant medical toxic effects and unpleasant adverse reactions, making them inappropriate for long-term use. Consequently, anticancer-drug resistance and relapse are frequent in certain situations. Thus, there is an urgent necessity to find effective antitumor medications that are specific and have few adverse consequences. Curcumin is a polyphenol derivative found in the turmeric plant (Curcuma longa L.), and provides chemopreventive, antitumor, chemo-, and radio-sensitizing properties. In this paper, we summarize the new nano-based formulations of polyphenolic curcumin because of the growing interest in its application against cancers and tumors. According to recent studies, the use of nanoparticles can overcome the hydrophobic nature of curcumin, as well as improving its stability and cellular bioavailability in vitro and in vivo. Several strategies for nanocurcumin production have been developed, each with its own set of advantages and unique features. Because the majority of the curcumin-based nanoformulation evidence is still in the conceptual stage, there are still numerous issues impeding the provision of nanocurcumin as a possible therapeutic option. To support the science, further work is necessary to develop curcumin as a viable anti-cancer adjuvant. In this review, we cover the various curcumin nanoformulations and nanocurcumin implications for therapeutic uses for cancer, as well as the current state of clinical studies and patents. We further address the knowledge gaps and future research orientations required to develop curcumin as a feasible treatment candidate.

Keywords: cancer immunotherapy; cancer treatment; curcumin nanoformulations; drug delivery system; nanocarriers; nanocurcumin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Figure 1
Figure 1
Chemical structure of curcumin in its enol and keto forms.
Figure 2
Figure 2
An overview of molecular mechanisms of curcumin against cancer.
Figure 3
Figure 3
Nano-based formulations of curcumin. Many curcumin-based nanoformulations have a significant impact on pharmaceutical applications, which are effective in the treatment of a wide range of human disorders due to their anti-cancer, antioxidant, antimicrobial, and antiinflammation, and even anti-Alzheimer properties. Most nanoformulations are capable of overcoming curcumin’s weak hydrophobicity, as well as its poor stability and poor cellular bioavailability. Such nanoformulations are utilized for long-term preservation and circulation throughout the body.
Figure 4
Figure 4
Anti-cancer activity of Gemini and dendrosomal nanocurcumin against various cancer cell lines was examined [155]. Curcumin’s ability to provoke apoptotic cell death, disturb cell cycle activity, and suppress proliferative behavior in cancer cells makes it a promising therapeutic target for human breast, colorectal, lung, carcinoma, prostate, melanoma, myeloma, liver, and pancreatic cancers.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Arruebo M., Vilaboa N., Sáez-Gutierrez B., Lambea J., Tres A., Valladares M., González-Fernández Á. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3:3279–3330. doi: 10.3390/cancers3033279. - DOI - PMC - PubMed
    1. D’Alterio C., Scala S., Sozzi G., Roz L., Bertolini G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin. Cancer Biol. 2020;60:351–361. doi: 10.1016/j.semcancer.2019.08.019. - DOI - PubMed
    1. Greenwell M., Rahman P.K.S.M. Medicinal Plants: Their Use in Anticancer Treatment. Int. J. Pharm. Sci. Res. 2015;6:4103–4112. doi: 10.13040/IJPSR.0975-8232.6(10).4103-12. - DOI - PMC - PubMed
    1. Khalifa S.A., Elias N., Farag M.A., Chen L., Saeed A., Hegazy M.E.F., Moustafa M.S., Abd El-Wahed A., Al-Mousawi S.M., Musharraf S.G., et al. Marine natural products: A source of novel anticancer drugs. Mar. Drugs. 2019;17:491. doi: 10.3390/md17090491. - DOI - PMC - PubMed

MeSH terms